Steroid-Dependent Nephrotic Syndrome; HypercalciuriaNCT07194213
Prevelance of Hypercalciuria in Children With Steroid Dependent Nephrotic Syndrome
An observational study of Steroid-Dependent Nephrotic Syndrome; Hypercalciuria and Steroid Dependent Nephrotic Syndrome, run by Sohag University at 2 sites in Egypt.
Trial summary
Prevelance of hypercalciurea in children with sterorid dependent nephrotic syndrome Read more about this study
- Who is it for?
- Ages 2 to 16 years
- Conditions the study is for
- Steroid-Dependent Nephrotic Syndrome; Hypercalciuria, Steroid Dependent Nephrotic Syndrome, Hupercalciurea
- How many people
- 50 participants
- Where
- 2 sitesEgypt
- Study dates
- 1 Jan 2024to Apr 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 16 years
- All sexes
- No healthy volunteers
- Child
Study population: Children diagnosed with steroid-dependent nephrotic syndrome who are being followed up at the pediatric nephrology clinic.
Who may be able to join
- - Age between 2 and 16 years.
- Diagnosis of steroid-dependent nephrotic syndrome (according to standard clinical criteria).
- Currently in remission or relapse while on steroid therapy.
Who cannot join
- - Children with congenital or secondary nephrotic syndrome.
- Presence of other chronic kidney diseases.
- Use of medications that affect calcium metabolism (other than steroids).
- Children with systemic diseases affecting bone or mineral metabolism.
Trial locations and contacts
2 sites in 1 country.
Egypt2 sites
Sohag university hospital
Sohag, 82524
Sohag university hospital
Sohag
About this study
Official title: Prevelance of Hypercalciuria in Children With Steroid Dependent Nephrotic Syndrome in Sohag University Hospital
Prevelance of hypercalciurea in children with sterorid dependent nephrotic syndrome
Read the detailed description
Prevelance of hypercalciurea in steroid dependent nephrotic syndrome
- Conditions
- Steroid-Dependent Nephrotic Syndrome; Hypercalciuria, Steroid Dependent Nephrotic Syndrome, Hupercalciurea
- Keywords
- Children, Pediatrics
- Medical subject headings
- Nephrotic Syndrome, Hypercalciuria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children with steroid dependent nephrotic syndrome | Participants will undergo urine analysis to measure calcium excretion in order to assess the prevalence of hypercalciuria. No experimental treatment will be given. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of hypercalciurea
Measured: At enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Sep 2025
- Study start1 Jan 2024
- Primary completion1 Jan 2026 (estimated)
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Steroid-Dependent Nephrotic Syndrome; HypercalciuriaStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Ewees Elsayed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07194213
- Sponsor's protocol ID
- Soh-Med--25-7-8MS
- Status last verified
- Sep 2025
- First submitted
- 19 Sep 2025
- Last updated
- 26 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified individual participant data (IPD) that underlie the results of the study will be made available upon reasonable request from the principal investigator, after publication of the main results.
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevelance of Hypercalciuria in Children With Steroid Dependent Nephrotic Syndrome in Sohag University Hospital
- ClinicalTrials.gov ID
- NCT07194213
- Acronym / sponsor ID
- Soh-Med--25-7-8MS
- Conditions
- Steroid-Dependent Nephrotic Syndrome; Hypercalciuria, Steroid Dependent Nephrotic Syndrome, Hupercalciurea
- Keywords
- Children, Pediatrics
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 1 Jan 2026 (estimated)
- Study completion
- Apr 2026 (estimated)
- First posted
- 26 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prevelance of hypercalciurea in children with sterorid dependent nephrotic syndrome
Detailed description
Prevelance of hypercalciurea in steroid dependent nephrotic syndrome
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Children with steroid dependent nephrotic syndrome | – | –Participants will undergo urine analysis to measure calcium excretion in order to assess the prevalence of hypercalciuria. No experimental treatment will be given. |
Who may qualify
- Ages
- 2 to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Children diagnosed with steroid-dependent nephrotic syndrome who are being followed up at the pediatric nephrology clinic.
Key inclusion criteria (3 listed)
- - Age between 2 and 16 years.
- Diagnosis of steroid-dependent nephrotic syndrome (according to standard clinical criteria).
- Currently in remission or relapse while on steroid therapy.
Key exclusion criteria (4 listed)
- - Children with congenital or secondary nephrotic syndrome.
- Presence of other chronic kidney diseases.
- Use of medications that affect calcium metabolism (other than steroids).
- Children with systemic diseases affecting bone or mineral metabolism.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of hypercalciurea
Time frame: At enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2025.
- Individual participant dataSharing planned: No. De-identified individual participant data (IPD) that underlie the results of the study will be made available upon reasonable request from the principal investigator, after publication of the main results.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Steroid-Dependent Nephrotic Syndrome; Hypercalciuria and Steroid Dependent Nephrotic Syndrome, run by Sohag University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of hypercalciurea (time frame: At enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2025.